Cell and Gene therapy (CGT) is considered as one of the most progressive advancements in this new ecosystem with extensive evaluations of multiple diseases and upcoming technologies. With the ongoing enhancements in CGT the potential to transform medicine increases which has brought a significant change for the treatment and potential cure of many intractable illnesses. In recent years, these therapies have proved clinically to be life-saving and also promise to offer personalization treatment for several diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.
Cell and Gene therapy continues to be a prominent and active area of research in genomics and cell biology which have permitted exciting progress in the development of novel and effective treatments for various diseases. With cell and gene therapies finally becoming a reality with ongoing hundreds of clinical trials and some of the major therapeutics breakthroughs already reaching the market, it is expected soon their will large number of approvals and launches in the market. So let’s come together to discuss the future of cell and gene therapy along with their applications, challenges and regulatory scenario.
In the pioneer edition of DBMR Cell and Gene Therapy Conference come join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together let’s move ahead in the future of medical science and technology.
Senior Manager - Research and Consulting
MRC Laboratory for Molecular Cell Biology (LMCB), UCL
Researcher - Department of Cardiology
Icahn School of Medicine at Mount Sinai
Founder and CEO
Stanford University School of Medicine
Advanced Specialist Biomedical Scientist
Imperial College London
George H. Kitzman Professor of Genetics
University of Florida College of Medicine
Cellular and Molecular Therapy, Powell Gene Therapy Center
American Gene Technologies